以岭药业2月3日获融资买入1427.81万元，融资余额7.13亿元

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Yiling Pharmaceutical, indicating a mixed market response with a slight increase in stock price and notable changes in financing activities [1][2] Group 2 - On February 3, Yiling Pharmaceutical's stock rose by 1.27%, with a trading volume of 295 million yuan. The financing buy-in amounted to 14.28 million yuan, while the financing repayment was 29.90 million yuan, resulting in a net financing outflow of 15.62 million yuan [1] - As of February 3, the total financing and securities lending balance for Yiling Pharmaceutical was 716 million yuan, with the financing balance accounting for 2.44% of the circulating market value, indicating a high level compared to the past year [1] - The company reported a decrease in operating revenue of 7.82% year-on-year for the first nine months of 2025, totaling 5.87 billion yuan, while the net profit attributable to shareholders increased by 80.33% to 1 billion yuan [2] - Yiling Pharmaceutical has distributed a total of 4.455 billion yuan in dividends since its A-share listing, with 1.838 billion yuan distributed over the past three years [2] - As of September 30, 2025, the number of shareholders decreased by 10.22% to 152,700, while the average circulating shares per person increased by 11.38% to 9,013 shares [2]